Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 374

Sort by

Sort Order Select

Journal Articles

Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Blood (2024) 144 (Supplement 1): 781.

https://doi.org/10.1182/blood-2024-200915

Published: 2024

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

Gvhd Therapy with Ruxolitinib Is Frequently Associated with Cytopenias, but Significant Decline in Hemoglobin Level Was Only Observed in Non-Responders at Day 28

Stephanie Gergoudis, Sean M. Devlin, Pamela Susman, Amandeep Singh, Stephanie Chinapen, Miguel Angel Perales, Doris M. Ponce

Blood (2024) 144 (Supplement 1): 7349.

https://doi.org/10.1182/blood-2024-210081

Published: 2024

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Richard J. Lin, Soo Jung Kim, Samantha Brown, Danielle M Hanley, Danielle E Engstler, Ioannis Politikos, Boglarka Gyurkocza, Roni Tamari, Esperanza B. Papadopoulos, Amethyst Saldia, Yetunde Aremu, Aaron D. Goldberg, Mark Blaine Geyer, Eytan M. Stein, Miguel Angel Perales, Beatriz Korc-Grodzicki, Sean M. Devlin, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 686.

https://doi.org/10.1182/blood-2024-207934

Published: 2024

Journal Articles

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 68.

https://doi.org/10.1182/blood-2024-208539

Published: 2024

Journal Articles

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 608.

https://doi.org/10.1182/blood-2024-207638

Published: 2024

Journal Articles

Bridging Radiotherapy May Decrease Inflammation Prior to CAR-T Cell Therapy

Roshal R. Patel, Alexander Tward, Beatrice Fregonese, Harper Hubbeling, Kaitlyn Lapen, Nikhil P. Mankuzhy, Sandeep S. Raj, Miguel-Angel Perales, Roni Shouval, Joachim Yahalom, Brandon S. Imber

Blood (2024) 144 (Supplement 1): 7164.

https://doi.org/10.1182/blood-2024-210814

Published: 2024

Journal Articles

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Melinda Cook, Grashma Vadakkel, Stephanie Chinapen, Miguel-Angel Perales, Roni Tamari, Esperanza B. Papadopoulos, Doris M. Ponce, Brian C. Shaffer, Andrew Lin

Blood (2024) 144 (Supplement 1): 7356.

https://doi.org/10.1182/blood-2024-200361

Published: 2024

Journal Articles

Validation of GMP Lentiviral Vector Production for CAR T-Cell Therapy in the Spanish Public Health System: Development of New QC Required By Aemps (Spanish FDA)

Maribel Lara Chica, María De La Rosa-Garrido, Blanca Arribas-Arribas, Miguel-Ángel Montiel-Aguilera, Raquel Muñoz-García, María Bermejo-González, Esteban Márquez-Pérez, Belén Sierro, Paola Hernández-Díaz, Beatriz Guijarro-Albaladejo, Inmaculada Carrasco Brocal, Virginia Escamilla Gómez, José Antonio Pérez-Simón, Gloria Carmona, Estefania Garcia-Guerrero

Blood (2024) 144 (Supplement 1): 7257.

https://doi.org/10.1182/blood-2024-207219

Published: 2024

Journal Articles

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Charlotte FM Hughes, Andrew Lin, Maria Bromberg, Sean M. Devlin, Amethyst Saldia, Danielle E Engstler, Danielle M Hanley, Yetunde Aremu, Martin Donach, Elizabeth Hoover, Oscar B Lahoud, Arnab Ghosh, Moneeza Walji, Miguel-Angel Perales, Michael Scordo, Sergio A. Giralt, Gunjan L. Shah, Parastoo B Dahi

Blood (2024) 144 (Supplement 1): 6492.

https://doi.org/10.1182/blood-2024-208310

Published: 2024

Journal Articles

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Blood (2024) 144 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2024-205005

Published: 2024

Journal Articles

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Blood (2024) 144 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2024-212274

Published: 2024

Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2024-198153

Published: 2024

Journal Articles

A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort

Brandon S. Imber, Anna Brosoff, Emma Roszak, Devin McAvoy, Kinga K. Hosszu, Alexander P. Boardman, Parastoo B Dahi, Gunjan L. Shah, Michael Scordo, Jae H. Park, Miguel-Angel Perales, Gilles Salles, Maria Lia Palomba, Joachim Yahalom

Blood (2024) 144 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2024-210156

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Blood (2024) 144 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2024-205548

Published: 2024

NARROW

Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Gvhd Therapy with Ruxolitinib Is Frequently Associated with Cytopenias, but Significant Decline in Hemoglobin Level Was Only Observed in Non-Responders at Day 28

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Bridging Radiotherapy May Decrease Inflammation Prior to CAR-T Cell Therapy

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Validation of GMP Lentiviral Vector Production for CAR T-Cell Therapy in the Spanish Public Health System: Development of New QC Required By Aemps (Spanish FDA)

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only